Interim analysis of the phase II study: Noninferiority study of doxorubicin with upfront dexrazoxane plus olaratumab for advanced or metastatic soft-tissue Sarcoma A C

Brian A. van Tine, Angela C. Hirbe, Peter Oppelt, Ashley E. Frith, Richa Rathore, Joshua D. Mitchell, Fei Wan, Shellie Berry, Michele Landeau, George A. Heberton, John Gorcsan, Peter R. Huntjens, Yoku Soyama, Justin M. Vader, Jose A. Alvarez-Cardona, Kathleen W. Zhang, Daniel J. Lenihan, Ronald J. Krone

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Interim analysis of the phase II study: Noninferiority study of doxorubicin with upfront dexrazoxane plus olaratumab for advanced or metastatic soft-tissue Sarcoma <sup>A</sup> C'. Together they form a unique fingerprint.

Medicine & Life Sciences